

Reference Data

Forecast for the Year ending March 31, 2020 Financial Highlights



	FY2017/3	FY2018/3	FY2019/3			FY2020/3 Forecast		
Billions of yen	Full Year	Full Year	1H	2H	Full Year	1H	2H	Full Year
Revenue	749.2	717.0	335.7	372.9	708.6	291.0	329.0	620.0
Operating Profit % vs Revenue	0.7 0.1%	56.2 7.8%	30.6 9.1%	52.0 13.9%	82.6 11.7%	17.5 6.0%	2.5 0.8%	20.0 3.2%
Profit before income taxes	3.0	56.2	33.8	54.1	87.9	20.1	2.9	23.0
% vs Revenue	0.4%	7.8%	10.1%	14.5%	12.4%	6.9%	0.9%	3.7%
Profit attributable to owners of the parent	3.9	34.7	22.8	43.7	66.5	16.3	0.7	17.0
% vs Revenue	0.5%	4.8%	6.8%	11.7%	9.4%	5.6%	0.2%	2.7%
ROE	0.7%	6.3%		11.2%			3%	
FCF	56.6	90.2	43.5			15.0		
Exchange rate : US \$ EURO	¥108 ¥119	¥111 ¥130	¥110 ¥130	¥112 ¥127	¥111 ¥128	¥109 ¥121	¥105 ¥120	¥107 ¥121

Note: From FY2019/3, a part of sales promotion expenses is deducted from revenue, which had been booked as SG&A previously. FY2019/3 Revenue is an amount after deducting ¥8.3B.

Forecast for the Year ending March 31, 2020: Financial Highlights by Segments




		FY2017/3	FY2018/3	FY19/3		FY20/3 Forecast			
Billions of yen		Full Year	Full Year	1H	2H	Full Year	1H	2H	Full Year
Imaging Products Business	Revenue Operating Profit	383.0 17.1 (28.1)	360.7 30.2 (36.0)	150.9 13.2 (13.6)	145.2 8.8 (9.0)	296.1 22.0 (22.6)	119.0 2.0 (2.0)	116.0 -12.0 (-7.0)	235.0 -10.0 (-5.0)
Precision	Revenue	248.0	226.3	121.6	152.9	274.5	115.1	139.9	255.0
Equipment	Operating	13.4	53.3	29.8	51.9	81.7	25.4	25.6	51.0
Business	Profit	(48.1)	(53.3)	(29.8)	(51.9)	(81.7)	(25.4)	(25.6)	(51.0)
Healthcare Business	Revenue Operating Profit	55.7 -0.6 (-0.1)	56.8 -3.2 (-3.2)	29.4 -2.3 (-2.3)	36.0 0.4 (0.4)	65.4 -1.9 (-1.9)	30.0 -1.2 (-1.2)	35.0 0.2 (0.2)	65.0 -1.0 (-1.0)
Industrial	Revenue	62.4	73.2	33.7	38.8	72.5	26.7	38.3	65.0
Metrology and	Operating	3.7	5.0	2.7	4.2	6.9	2.4	1.6	4.0
Others	Profit	(5.5)	(7.8)	(3.5)	(4.0)	(7.5)	(2.4)	(1.6)	(4.0)
Corporate P/L	Revenue	–	-	-	-	-	-	-	–
non-attributable to any	Operating	-32.8	-29.1	-12.8	-13.3	-26.1	-11.1	-12.9	-24.0
reportable segments	Profit	(-27.5)	(-29.1)	(-12.8)	(-12.8)	(-25.6)	(-9.4)	(-12.9)	(-22.3)
Consolidated	Revenue	749.2	717.0	335.7	372.9	708.6	291.0	329.0	620.0
	Operating	0.7	56.2	30.6	52.0	82.6	17.5	2.5	20.0
	Profit	(54.1)	(64.9)	(31.8)	(52.6)	(84.4)	(19.2)	(7.5)	(26.7)

Note: From FY2019/3, a part of sales promotion expenses is deducted from revenue, which had been booked as SG&A previously. FY2019/3 Revenue is an amount after deducting ¥8.3B. Figures in parentheses are the operating profit excluding the restructuring relevant expenses.

First Half of the Year ending March 31, 2020: Financial Position Breakdown





Note: A breakdown of interest-bearing debt as of September 30, 2019 is ¥29.9B in bonds and ¥111.4B in other borrowings. Equity ratio is ratio of equity attributable to owners of the parent to total assets.


Cash and Cash Equivalents excludes time deposits with maturities of thee months or more.


Forecast for the Year ending March 31, 2020: Capital Expenditures, Depreciation and Inventory



CAPITAL EXPENDITURES, DEPRECIATION

INVENTORY BREAKDOWN






Note: In FY2020/3, "CAPITAL EXPENDITURES" includes the leased assets of approximately ¥3.0B upon the adoption of IFRS16.

"DEPRECIATION" includes the amortization of capitalized R&D costs from the FY2018/3 and depreciation of the leased asset of approx. ¥4.0B in FY2020/3, as mentioned above.


First Half of the Year ending March 31, 2020: Revenue Breakdown








BY REGION




Forecast for the Year ending March 31, 2020: R&D Expenditures



R&D EXPENDITURES




R&D EXPENDITURES BREAKDOWN



Note: R&D expenditures after FY2018/3 includes capitalization of some development expenditure.

Cash Flow History






Note: FCF (free cash flows) = CF from operating activities + CF from investing activities; Japanese Standard is employed for FY2015/3 and prior, and IFRS is adopted for FY2016/3 and after. FCF + CF from financial activities + Effect of exchange rate changes on cash and cash equivalents = net increase (decrease) in cash and cash equivalents

Shareholder Return History and Forecast






Note: Buy-back of shares at approx. ¥10.0B was conducted in Q1 of FY2020/3. Another buy-back of approx. ¥30B is planned in the period between Q3 and Q4 of FY2020/3.

Imaging Products Business: Sales Units






Forecast for the Year ending March 31, 2020: Precision Equipment Business Sales Units






SEMICONDUCTOR LITHOGRAPHY SYSTEMS SALES BY TECHNOLOGY (INCL. REFURBISHED)



Note: The unit sales of new semiconductor lithography systems is 17 units in FY2018/3, 21 units in FY2019/3 and 30 units (forecast) in FY2020/3.


Precision Equipment Business: Sales Units





Precision Equipment Business: Sales Units





Forecast for the Year ending March 31, 2020: Foreign Exchange Impact



	Exchange rate	Financial Impact from Fluctuation by 1 yen			
	FY2020/3 Forecast for 2H	Revenue 2H	Operating Profit 2H		
US \$	¥105	Approx. ¥1.3billion	Approx. ¥0.2billion		
EURO	¥120	Approx. ¥0.3billion	Approx. ¥0.2billion		

Note: The foreign exchange impact above is made on the assumption that emerging-market currencies move according to the influence of US\$ and Euro.

Disclaimer Regarding Forecast and Projections



Forward-looking statements for earnings and other performance data contained herein are based on information currently available to the Company, and all potential risks and uncertainties are taken into account. The Company asks that investors understand that changes in conditions may cause actual performance to significantly differ from these projections.

